|
MLF1IP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.53340004319602E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.97059995993487E-09 |
| Normal-vs-Stage2 |
7.302300E-03 |
| Normal-vs-Stage3 |
5.347000000544E-07 |
| Normal-vs-Stage4 |
1.53365999999711E-05 |
| Stage1-vs-Stage2 |
2.382300E-03 |
| Stage1-vs-Stage3 |
6.590200E-01 |
| Stage1-vs-Stage4 |
9.865800E-01 |
| Stage2-vs-Stage3 |
4.864100E-03 |
| Stage2-vs-Stage4 |
2.836200E-02 |
| Stage3-vs-Stage4 |
7.746200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.46320000349709E-09 |
| Normal-vs-AfricanAmerican |
3.158200E-03 |
| Normal-vs-Asian |
9.72190000000372E-05 |
| Caucasian-vs-AfricanAmerican |
9.475800E-01 |
| Caucasian-vs-Asian |
2.244300E-02 |
| AfricanAmerican-vs-Asian |
3.299200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.57220000036085E-07 |
| Normal-vs-Female |
7.52429996087045E-09 |
| Male-vs-Female |
7.204600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.90249976567736E-10 |
| Normal-vs-Age(41-60Yrs) |
6.01600000038616E-07 |
| Normal-vs-Age(61-80Yrs) |
3.75220000004006E-06 |
| Normal-vs-Age(81-100Yrs) |
9.057800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.140600E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.906600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.773600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.413400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.681800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.619800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.154300E-02 |
| Classical-VS-Follicular |
3.392100E-02 |
| Classical-VS-Other |
8.306600E-01 |
| Classical-VS-Normal |
3.64679997311157E-09 |
| Tall-VS-Follicular |
4.558500E-04 |
| Tall-VS-Other |
4.886000E-01 |
| Tall-VS-Normal |
3.77340048096642E-10 |
| Follicular-VS-Other |
3.988000E-01 |
| Follicular-VS-Normal |
4.244700E-04 |
| Other-VS-Normal |
1.116620E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.88280000046737E-07 |
| Normal-vs-N1 |
8.51250000044601E-07 |
| N0-vs-N1 |
8.186000E-01 |
|
|
